Inhibition of FOXM1 following siRNA treatment reverses cisplatin resistance in MCF-7-CISR breast cancer cells, suggesting that FOXM1 is a potential therapeutic target in cisplatin-resistant ER+ breast cancer [74]. Here, FOXM1 is linked to breast cancer.